ABSTRACT
BACKGROUND Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patient-reported outcomes with data from digital health records to understand predictors and impacts of SARS-CoV-2 infection.
METHODS INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of SARS-CoV-2 infection in eight regions across the US. Included are adults fluent in English or Spanish, with self-reported symptoms suggestive of acute SARS-CoV-2 infection, enrolled within 42 days of having a US Food and Drug Administration approved SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test). Recruitment occurs in-person, by phone or email, and through online advertisement. A secure online platform is used to facilitate the collation of consent-related materials, digital health records, and responses to self-administered surveys. Participants will be followed for up to 18 months, with patient-reported outcomes collected every three months via survey and linked to concurrent digital health data; follow-up includes no in-person involvement. Our maximum expected enrollment is 4,800 participants, including 3,600 SARS-CoV-2 positive and 1,200 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in individuals with and without infection. Patient-reported outcomes include self-reported health function and status, as well as clinical outcomes including health system encounters and new diagnoses.
RESULTS Participating sites obtained institutional review board approval. Enrollment and follow-up are ongoing.
CONCLUSIONS This study will characterize medium and long-term sequelae of SARS-CoV-2 infection among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.
Competing Interest Statement
FINANCIAL DISCLOSURE The Innovative Support for Patients with SARS-COV-2 Infections (INSPIRE) Registry is funded by the Centers for Disease Control and Prevention (CDC), National Center of Immunization and Respiratory Diseases (NCIRD) (contract number: 75D30120C08008; co-PIs Bala Hota, MD, and Robert A. Weinstein, MD). Partners from the CDC assisted with study design, the preparation of this protocol manuscript and the decision to publish this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). No others sponsors or funders (other than the named authors) played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Additionally, I read the journal's policy and the authors of this manuscript have the following financial disclosures: JGE is an Editor for UpToDate on topics related to SARS-CoV-2 (https://www.uptodate.com). GN receives salary support from Leonard A Cobb~ Medic One Foundation (https://www.mediconefoundation.org/about/who-we-are/), ZOLL Circulation Inc. (https://www.zoll.com/contact/careers-at-zoll/tms), General Electric Health Care Inc. (https://www.gehealthcare.com/about/about-ge-healthcare-systems), Kestra Medical Technologies (https://kestramedical.com/), Abiomed Inc. (https://www.abiomed.com/), CPR Therapeutics Inc. (https://www.cprtherapeutics.com/), Pagonia Medical Inc. (no related website), and Medical Developments International (https://medicaldev.com/). AHI participates in the National Emergency Cardiovascular Care Committee (Science Subcommittee) of the American Heart Association (https://www.heart.org/) and is an unpaid member of the Clinical Advisory Board for Stryker (https://www.stryker.com/us/en/index.html). HMK received expenses and/or personal fees from UnitedHealth (https://www.uhc.com/), IBM Watson Health (https://www.ibm.com/watson-health?cm_sp=Scheduler-_-CopyChng2-_-C), Element Science (https://www.elementscience.com/), Aetna (https://www.aetna.com/), Facebook (https://www.facebook.com/), the Siegfried and Jensen Law Firm (https://www.siegfriedandjensen.com/), Arnold and Porter Law Firm (https://www.theworldlawgroup.com/member-firms/arnold-porter), Martin/Baughman Law Firm (https://www.martinbaughman.com/practice-areas/), F-Prime (https://fprimecapital.com/), and the National Center for Cardiovascular Diseases in Beijing (http://english.pumc.edu.cn/centers/62.html). He is a co-founder of Refactor Health (https://www.refactorhealth.com/) and had grants and/or contracts from the Centers for Medicare & Medicaid Services (https://www.cms.gov/), Medtronic (https://www.medtronic.com/us-en/index.html), the U.S. Food and Drug Administration (https://www.fda.gov/), Johnson & Johnson (https://www.jnj.com/), and the Shenzhen Center for Health Information (http://www.sz.gov.cn/en/). MT provided consulting as a paid medical advisor to Visby Medical (https://www.visbymedical.com/) and Roche Molecular Diagnostics (https://diagnostics.roche.com/) which both produce laboratory tests for COVID-19. The authors not otherwise listed here have no financial disclosures. COMPETING INTERESTS I read the journal's policy and the authors of this manuscript have the following competing interests: HMK is co-founder for HugoHealth.
Clinical Trial
ClinicalTrials.gov Identifier: NCT04610515
Funding Statement
The study team is receiving financial support from the Centers for Disease Control and Prevention (CDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval of this protocol has been obtained at each individual site including Rush University (protocol number: 20030902, approved 3/14/2020), Yale University (2000027976, approved 4/30/2020), the University of Washington (UW Human Subjects Division, STUDY00009920, approved 4/2/2020), Thomas Jefferson University (20p.1150, approved 1/21/2021), the University of Texas Southwestern Medical Center (STU 2020-1352, approved 2/3/2021), the University of Texas, Houston (HSC-MS-20-0981, approved 9/10/2020), the University of California, San Francisco (20-32222, approved 1/25/2021) and the University of California, Los Angeles (20-001683, approved 12/18/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos